FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.
Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.
FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.
A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.
FDA approved a novel device to treat breathing difficulty associated with severe emphysema.
A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.
FDA’s approval of a cannabidiol (CBD) medicine to treat seizures associated with 2 severe forms of epilepsy is a positive sign for other CBD drugs under development.
While FDA has approved other continuous glucose monitoring (CGM) systems, it just approved the first system that includes a fully implantable sensor to detect glucose.
The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.
A generic manufacturer is fighting a restraining order against its sale of one of the first generic versions of buprenorphine and naloxone (Suboxone) sublingual film to treat opioid dependence, after FDA approved them late last week.